San Diego, CA—Although tyrosine kinase inhibitors (TKIs) including imatinib (Gleevec), nilotinib (Tasigna), and dasatinib (Sprycel), have dramatically improved outcomes in patients with chronic myeloid leukemia (CML), the costs of these drugs have spiraled out of control, causing some patients to stop treatment or cut their dosage because of financial toxicity. Data presented at the 2016 American Society of Hematology meeting show that it is possible for some patients with CML to reduce their TKI dose by 50% and maintain remission, perhaps even stop treatment altogether once deep and durable remission has been achieved after approximately 5 years of treatment.
San Diego, CA—Induction therapy with a liposomal formulation of cytarabine and daunorubicin CPX-351 (Vyxeos) is superior to cytarabine plus daunorubicin (7+3 regimen) in patients with acute myeloid leukemia (AML), according to a subgroup analysis of a large phase 3 clinical trial that was presented at the 2016 American Society of Hematology (ASH) meeting.
San Diego, CA—Targeting a second-­generation tyrosine kinase inhibitor (TKI) in mutation-specific chronic myeloid leukemia (CML) led to deep and durable responses that were maintained beyond 3 years in some cases, reported Neil Shah, MD, PhD, Department of Medicine/Hematology-Oncology, University of California San Francisco, during a poster presentation at the 2016 American Society of Hematology meeting.
San Diego, CA—Maintenance therapy with lenalidomide (Revlimid) after frontline chemotherapy markedly prolonged progression-free survival (PFS) in patients with high-risk chronic lymphocytic leukemia (CLL), according to interim results from a phase 3 study presented at the 2016 American Society of Hematology meeting.
  • 5-Year Ibrutinib Therapy in Treatment-Naïve Patients with Relapsed or Refractory CLL or SLL
  • Updated Safety and Efficacy Data for Ibrutinib as First-Line Treatment in Older Patients with CLL or SLL
  • Long-Term Follow-Up of Chlorambucil plus Rituximab Combination as Frontline Therapy for Elderly and/or Unfit Patients with CLL, Including Risk Stratification
  • Reviewing the Demographics and First-Line Treatment Patterns in Patients with CLL
  • Comparing Healthcare Utilization of 2 Drug Regimens in Patients with CLL

A durable complete response was achieved in a high proportion of adults with refractory B-cell malignancies who received CD19+ chimeric antigen receptor (CAR) T-cells made up of a defined 1:1 ratio of CD8+ and CD4+ cells.

Chimeric antigen receptor (CAR) T-cells have saved lives in some patients with acute lymphoblastic leukemia (ALL) who had run out of other treatment options. This type of immunotherapy is making inroads in other hematologic malignancies as well, but it is still being studied in very sick patients.

Dose-optimized nilotinib (Tasigna) increased the rates of major molecular response in patients with newly diagnosed chronic myeloid leukemia (CML) in the chronic phase (CP) in the Evaluating Nilotinib Effi­cacy and Safety in Clinical Trials-Ex­tending Molecular Responses (ENEST­xtnd) study.
Ibrutinib (Imbruvica) significantly reduced the risk for disease progression or death compared with standard treatment with chlorambucil (Leukeran) in older (aged ≥65 years) treatment-naïve patients with chronic lymphocytic leukemia (CLL). Ibrutinib achieved a 91% reduction in the risk for disease progression and an 84% reduction in the risk for death compared with chlorambucil.
Idelalisib (Zydelig) reduced the risk for disease progression and death when added to bendamustine (Treanda) plus rituximab (Rituxan) versus bendamustine plus rituximab alone in patients with relapsed or refractory chronic lymphocytic leukemia.
Page 2 of 6
Results 11 - 20 of 52
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME